Fulgent Genetics Inc (NASDAQ: FLGT)’s stock price has gone decline by -0.20% in comparison to its previous close of $20.1, however, the company has experienced a 2.35% increase in its stock price over the last five trading days. prnewswire.com reported 2025-07-02 that NEW YORK, July 2, 2025 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Is It Worth Investing in Fulgent Genetics Inc (NASDAQ: FLGT) Right Now?
FLGT has 36-month beta value of 0.84. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy”, 1 as “overweight”, 2 as “hold”, and 0 as “sell”.
The public float for FLGT is 19.61M, and currently, short sellers hold a 8.40% ratio of that float. The average trading volume of FLGT on July 04, 2025 was 322.53K shares.
FLGT’s Market Performance
The stock of Fulgent Genetics Inc (FLGT) has seen a 2.35% increase in the past week, with a -5.24% drop in the past month, and a 13.85% gain in the past quarter. The volatility ratio for the week is 2.81%, and the volatility levels for the past 30 days are at 2.95% for FLGT. The simple moving average for the past 20 days is -1.65% for FLGT’s stock, with a 6.13% simple moving average for the past 200 days.
Analysts’ Opinion of FLGT
Many brokerage firms have already submitted their reports for FLGT stocks, with UBS repeating the rating for FLGT by listing it as a “Neutral”. The predicted price for FLGT in the upcoming period, according to UBS is $35 based on the research report published on December 07, 2023 of the previous year 2023.
Piper Sandler, on the other hand, stated in their research note that they expect to see FLGT reach a price target of $40, previously predicting the price at $65. The rating they have provided for FLGT stocks is “Neutral” according to the report published on December 08th, 2022.
Credit Suisse gave a rating of “Outperform” to FLGT, setting the target price at $65 in the report published on August 25th of the previous year.
FLGT Trading at 0.19% from the 50-Day Moving Average
After a stumble in the market that brought FLGT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.11% of loss for the given period.
Volatility was left at 2.95%, however, over the last 30 days, the volatility rate increased by 2.81%, as shares sank -5.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +8.67% upper at present.
During the last 5 trading sessions, FLGT rose by +2.35%, which changed the moving average for the period of 200-days by -10.25% in comparison to the 20-day moving average, which settled at $20.40. In addition, Fulgent Genetics Inc saw 0.10% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FLGT starting from Gao Hanlin, who sold 754 shares at the price of $20.29 back on Jun 02 ’25. After this action, Gao Hanlin now owns 961,281 shares of Fulgent Genetics Inc, valued at $15,299 using the latest closing price.
Xie Jian, the President and COO of Fulgent Genetics Inc, sale 1,135 shares at $20.29 during a trade that took place back on Jun 02 ’25, which means that Xie Jian is holding 371,496 shares at $23,030 based on the most recent closing price.
Stock Fundamentals for FLGT
Current profitability levels for the company are sitting at:
- -0.22% for the present operating margin
- 0.38% for the gross margin
The net margin for Fulgent Genetics Inc stands at -0.14%. The total capital return value is set at -0.06%. Equity return is now at value -3.61%, with -3.35% for asset returns.
Based on Fulgent Genetics Inc (FLGT), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 1.22. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -268.99.
Currently, EBITDA for the company is -48.99 million with net debt to EBITDA at 1.26. When we switch over and look at the enterprise to sales, we see a ratio of 1.88. The receivables turnover for the company is 4.09for trailing twelve months and the total asset turnover is 0.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.32.
Conclusion
To put it simply, Fulgent Genetics Inc (FLGT) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
